Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 11/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 9/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19483631 | 0.91 | THRB (0.50) | RAB9AHPGDSMN1; SMN2POLBTHRB | |
| SCHEMBL19487504 | 0.88 | RAB9A (0.44) | RAB9AHPGDSMN1; SMN2POLBTHRB | |
| SCHEMBL19487694 | 0.86 | RAB9A (0.42) | RAB9AHPGDSMN1; SMN2POLBTHRB | |
| SCHEMBL19487693 | 0.82 | RAB9A (0.43) | RAB9AHPGDSMN1; SMN2POLBTHRB | |
| SCHEMBL19484164 | 0.81 | SLC6A5 (0.41) | RAB9AHPGDSMN1; SMN2THRBNPC1 | |
| SCHEMBL19483622 | 0.81 | THRB (0.48) | RAB9AHPGDSMN1; SMN2POLBTHRB | |
| SCHEMBL19483625 | 0.80 | THRB (0.52) | RAB9AHPGDSMN1; SMN2POLBTHRB | |
| SCHEMBL19488049 | 0.80 | RAB9A (0.42) | RAB9AHPGDSMN1; SMN2POLBTHRB | |
| SCHEMBL19483610 | 0.79 | THRB (0.46) | RAB9AHPGDSMN1; SMN2POLBTHRB | |
| SCHEMBL19483658 | 0.79 | THRB (0.51) | RAB9AHPGDSMN1; SMN2POLBTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10251396-B2 | Amide compound and use of same for noxious arthropod control | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2019-04-09 | — | — | US | disclosed |
| US-20170295789-A1 | AMIDE COMPOUND AND USE OF SAME FOR NOXIOUS ARTHROPOD CONTROL | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170295789-A1 | AMIDE COMPOUND AND USE OF SAME FOR NOXIOUS ARTHROPOD CONTROL | OPRM1, TRPA1, L3MBTL3 | RAB9A 753/4885HPGD 2430/4885SMN1; SMN2 1274/4885 |
| US-10251396-B2 | Amide compound and use of same for noxious arthropod control | OPRM1, TRPA1, L3MBTL3 | RAB9A 753/4885HPGD 2430/4885SMN1; SMN2 1274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.